Crohn's disease intestinal CD4+ T cells have impaired interleukin-10 production which is not restored by probiotic bacteria

References

• Nagler-Anderson C. Tolerance and immunity in the intestinal immune system. Crit Rev Immunol 2000; 20: 103–20
   PubMed Web of Science ®Google Scholar
• Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, Meyer zum Buschenfelde KH. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995; 102: 448–55
   PubMed Web of Science ®Google Scholar
• Plevy SE, Landers CJ, Prehn J, Carramanzana NM, Deem RL, Shealy D, et al. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol 1997; 159: 6276–82
   PubMed Web of Science ®Google Scholar
• Camoglio L, Te Velde AA, Tigges AJ, Das PK, Van Deventer SJ. Altered expression of interferon-gamma and interleukin-4 in inflammatory bowel disease. Inflamm Bowel Dis 1998; 4: 285–90
   PubMed Web of Science ®Google Scholar
• Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003; 3: 253–7
   PubMed Web of Science ®Google Scholar
• Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389: 737–42
   PubMed Web of Science ®Google Scholar
• Weiner HL. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev 2001; 182: 207–14
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151–64
   PubMed Web of Science ®Google Scholar
• Makita S, Kanai T, Oshima S, Uraushihara K, Totsuka T, Sawada T, et al. CD4 + CD25bright T cells in human intestinal lamina propria as regulatory cells. J Immunol 2004; 173: 3119–30
   PubMed Web of Science ®Google Scholar
• Maul J, Loddenkemper C, Mundt P, Berg E, Giese T, Stallmach A, et al. Peripheral and intestinal regulatory CD4 + CD25high T cells in inflammatory bowel disease. Gastroenterology 2005; 128: 1868–78
   PubMed Web of Science ®Google Scholar
• Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993; 75: 263–74
   PubMed Web of Science ®Google Scholar
• Schreiber S, Heinig T, Thiele HG, Raedler A. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 1995; 108: 1434–44
   PubMed Web of Science ®Google Scholar
• Braunstein J, Qiao L, Autschbach F, Schurmann G, Meuer S. T cells of the human intestinal lamina propria are high producers of interleukin-10. Gut 1997; 41: 215–20
   PubMed Web of Science ®Google Scholar
• ten Hove T, The OF, Berkhout M, Bruggeman JP, Vyth-Dreese FA, Slors JF, et al. Expression of CD45RB functionally distinguishes intestinal T lymphocytes in inflammatory bowel disease. J Leuk Biol 2004; 75: 1010–5
   PubMed Web of Science ®Google Scholar
• Hart AL, Kamm MA, Knight SC, Stagg AJ. Quantitative and functional characteristics of intestinal-homing memory T cells: analysis of Crohn's disease patients and healthy controls. Clin Exp Immunol 2004; 135: 137–45
   PubMed Web of Science ®Google Scholar
• Reid G, Sanders ME, Gaskins HR, Gibson GR, Mercenier A, Rastall R, et al. New scientific paradigms for probiotics and prebiotics. J Clin Gastroenterol 2003; 37: 105–18
   PubMed Web of Science ®Google Scholar
• Madsen KL, Doyle JS, Jewell LD, Tavernini MM, Fedorak RN. Lactobacillus species prevent colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999; 116: 1107–14
   PubMed Web of Science ®Google Scholar
• Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999; 13: 1103–8
   PubMed Web of Science ®Google Scholar
• Rachmilewitz D, Katakura K, Karmeli F, Hayashi T, Reinus C, Rudensky B, et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004; 126: 520–8
   PubMed Web of Science ®Google Scholar
• Sheil B, McCarthy J, O'Mahony L, Bennett MW, Ryan P, Fitzgibbon JJ, et al. Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis. Gut 2004; 53: 694–700
   PubMed Web of Science ®Google Scholar
• Von der Weid T, Bulliard C, Schiffrin EJ. Induction by a lactic acid bacterium of a population of CD4(+) T cells with low proliferative capacity that produce transforming growth factor beta and interleukin-10. Clin Diagn Lab Immunol 2001; 8: 695–701
   PubMedGoogle Scholar
• Di Giacinto C, Marinaro M, Sanchez M, Strober W, Boirivant M. Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing IL-10 and IL-10-dependent TGF-beta-bearing regulatory cells. J Immunol 2005; 174: 3237–46
   PubMed Web of Science ®Google Scholar
• Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 2002; 51: 405–9
   PubMed Web of Science ®Google Scholar
• Marteau P, Lemann M, Seksik P, Laharie D, Colombel JF, Bouhnik Y, et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double-blind, placebo-controlled GETAID trial. Gut 2006; 55: 700–5
   Google Scholar
• Agnholt J, Kaltoft K. In situ activated intestinal T cells expanded in vitro – without addition of antigen – produce IFN-gamma and IL-10 and preserve their function during growth. Exp Clin Immunogenet 2001; 18: 213–25
   PubMedGoogle Scholar
• Bender A, Sapp M, Schuler G, Steinman RM, Bhardwaj N. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Methods 1996; 196: 121–35
   PubMed Web of Science ®Google Scholar
• Fedorak RN, Gangl A, Elson CO, Rutgeerts P, Schreiber S, Wild G, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 2000; 119: 1473–82
   PubMed Web of Science ®Google Scholar
• Kelsen J, Agnholt J, Hoffmann HJ, Rømer JL, Hvas CL, Dahlerup JF. FoxP3 + CD4 + CD25+ T cells with regulatory properties can be cultured from colonic mucosa of patients with Crohn's disease. Clin Exp Immunol 2005; 141: 549–57
   PubMed Web of Science ®Google Scholar
• Kramer M, Netea MG, de Jong DJ, Kullberg BJ, Adema GJ. Impaired dendritic cell function in Crohn's disease patients with NOD2 3020insC mutation. J Leukoc Biol 2006; 79: 860–6
   PubMed Web of Science ®Google Scholar
• Niessner M, Volk BA. Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clin Exp Immunol 1995; 101: 428–35
   PubMed Web of Science ®Google Scholar
• Akagi S, Hiyama E, Imamura Y, Takesue Y, Matsuura Y, Yokoyama T. Interleukin-10 expression in intestine of Crohn disease. Int J Mol Med 2000; 5: 389–95
   PubMed Web of Science ®Google Scholar
• Autschbach F, Braunstein J, Helmke B, Zuna I, Schurmann G, Niemir ZI, et al. In situ expression of interleukin-10 in noninflamed human gut and in inflammatory bowel disease. Am J Pathol 1998; 153: 121–30
   PubMed Web of Science ®Google Scholar
• Ebert EC, Mehta V, Das KM. Activation antigens on colonic T cells in inflammatory bowel disease: effects of IL-10. Clin Exp Immunol 2005; 140: 157–65
   PubMed Web of Science ®Google Scholar
• Gasche C, Scholmerich J, Brynskov J, D'Haens G, Hanauer SB, Irvine EJ, et al. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000; 6: 8–15
   PubMed Web of Science ®Google Scholar
• Best WR, Becktel JM, Singleton JW, Kern F, Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439–44
   PubMed Web of Science ®Google Scholar
• D'Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998; 114: 262–7
   PubMed Web of Science ®Google Scholar
• Agnholt J, Kelsen J, Brandsborg B, Jakobsen NO, Dahlerup JF. Increased production of granulocyte-macrophage colony-stimulating factor in Crohn's disease: a possible target for infliximab treatment. Eur J Gastroenterol Hepatol 2004; 16: 649–55
   PubMed Web of Science ®Google Scholar